Clinical trials: Non-muscular Invasive Bladder Cancer
Bladder Cancer
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.
- Trial name
- OU-SCC-ABC (NCT03892642)
- Testing
- Avelumab, BCG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Oklahoma
Non-muscle Invasive Bladder Cancer
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC).
- Trial name
- NCT06126796
- Testing
- CxBladder Monitor, Cystoscopy
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Mayo Clinic
Non-Muscle Invasive Bladder Carcinoma
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time)…
- Trial name
- NCT07474519
- Testing
- Accelerometry, BCG Solution, Electronic Health Record Review
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
TCC
The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer
Purpose: to demonstrate a 10% recurrence risk reduction for patients treated with Hypersal versus normal saline immediately following TURBT. Design: prospective randomized double-blind placebo controlled trial.
- Trial name
- NCT04671407
- Testing
- Hypertonic Saline
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Kaplan Medical Center
Urinary Bladder Neoplasms
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder…
- Trial name
- NCT04430036
- Testing
- AGEN1884, AGEN2034, Cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bladder Cancer
Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study
This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention" refers to surveillance based on the European Association of Urology (EAU) guidelines and the "control" refers to surveillance based on…
- Trial name
- NCT02298998
- Testing
- Intervention, Control
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bladder Cancer
Bakircay University Cigli Training and Research Hospital
The aim of the study is to investigate the oncological outcomes of obturator nerve blockade in patients with lateral wall localized non-muscle invasive bladder cancer
- Trial name
- BUCEAH (NCT04683536)
- Testing
- Obturator nerve blockade
- Volunteers
- 106 people
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Non-muscle Invasive Bladder Cancer
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one…
- Trial name
- eRapa (NCT04375813)
- Testing
- eRapa
- Where
- 2 sites in United States
- Volunteers
- 166 people
- Sponsor
- Robert Svatek
Bladder Cancer
Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study
The aim of the study is to prospectively assess the role of mpMRI as a non invasive method for assessment of possible residual tumor after initial resection of non muscle invasive bladder tumor.
- Trial name
- NCT03914001
- Testing
- mpMRI, Second look TURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Urinary Bladder Neoplasms
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Background: Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the immune system find and destroy cancer cells.
- Trial name
- NCT03258593
- Testing
- Durvalumab, Vicineum, Acetaminophen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Superficial Bladder Cancer, Bladder Cancer
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index…
- Trial name
- TROJAN (NCT03379909)
- Testing
- Metformin
- Where
- 3 sites in Netherlands
- Volunteers
- 49 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non-Muscle Invasive Bladder Cancer
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Aim: To investigate the feasibility and tolerability of the Olympus Soltive laser in treatment of large recurrent low-grade Ta tumours in an outpatient setting.
- Trial name
- OPTIMA (NCT05337397)
- Testing
- Laser ablation
- Where
- Denmark
- Volunteers
- 145 people
- Sponsor
- Jørgen Bjerggaard Jensen
Bladder Cancer
Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study
The primary objective of this prospective, single-centre study is to establish the clinical performance characteristics of Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems in comparison to the methods currently…
- Trial name
- NCT03715660
- Testing
- Xpert bladder cancer monitor
- Where
- Egypt
- Volunteers
- 198 people
- Sponsor
- Mansoura University
Non-muscle-invasive Bladder Cancer
T-Control® Safety for Cytostatics Management
The goal of this pilot clinical trial is to know if this study is feasable in terms of design, recruitment and interventions, as well as gather preliminary data to determine if the T-Control® catheter is safer than the…
- Trial name
- NCT06678633
- Testing
- T-Control® (experimental), Folysil® (control)
- Volunteers
- 16 people
- Sponsor
- Rethink Medical SL
Bladder Cancer
Blue Light Cystoscopy With Cysview® Registry
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
- Trial name
- BLCCR (NCT02660645)
- Testing
- Hexaminolevulinate hydrochloride (HCL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- Where
- 23 sites in United States
- Volunteers
- 4,400 people
- Sponsor
- Photocure
Bladder Cancer
A Study for Treatment of Superficial Bladder Cancer Using OGX-427
This is a single centre, open label, phase I dose escalation trial using a modified accelerated titration design. Patients with superficial bladder tumour (Ta or T1) or CIS and candidates for transurethral resection or muscle…
- Trial name
- NCT00959868
- Testing
- OGX-427
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Vancouver Coastal Health
Non-muscle Invasive Bladder Cancer, Urinary Biomarker
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
The study aims to evaluate the potential clinical impact of a highly sensitive urinary marker, the Xpert Bladder Cancer Monitor, regarding possible reduction in number of flexible cystoscopies in an outpatient setting without…
- Trial name
- SEALS Xpert (NCT04100733)
- Testing
- Xpert Bladder Cancer Monitor, Flexible cystoscopy (WL/NBI) and urinary cytology
- Where
- 3 sites in Denmark
- Volunteers
- 392 people
- Sponsor
- Jørgen Bjerggaard Jensen
Non-muscle-invasive Bladder Cancer
A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years…
- Trial name
- ANTICIPATE X (NCT03664258)
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 13 sites in Austria, Czechia and 7 more
- Volunteers
- 852 people
- Sponsor
- Cepheid
Bladder Cancer, Liquid Biopsy
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression.
- Conditions
- Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
- Trial name
- NCT07187635
- Testing
- Second Transurethral Resection of Bladder Tumor (re-TURBT), utDNA Testing (Urine Tumor DNA Detection)
- Where
- 7 sites in China
- Volunteers
- 350 people
- Sponsor
- Tianjin Medical University Second Hospital